The expected value of sample information calculations for external validation of risk prediction models

Mohsen Sadatsafavi* Andrew J Vickers Tae Yoon Lee Paul Gustafson Laure Wynants

January 04, 2024

Abstract

In designing external validation studies of clinical prediction models, contemporary sample size calculation methods are based on the frequentist inferential paradigm. One of the widely reported metrics of model performance is net benefit (NB), and the relevance of conventional inference around NB as a measure of clinical utility is doubtful. Value of Information methodology quantifies the consequences of uncertainty in terms of its impact on clinical utility of decisions. We introduce the expected value of sample information (EVSI) for validation as the expected gain in NB from conducting an external validation study of a given size. We propose algorithms for EVSI computation, and in a case study demonstrate how EVSI changes as a function of the amount of current information and future study's sample size. Value of Information methodology provides a decision-theoretic lens to the process of planning a validation study of a risk prediction model and can complement conventional methods when designing such studies.

Introduction

Clinical prediction models that quantify the risk of medically significant events are a key aspect of individualized medicine. Before being trusted for clinical use in a target population, a model needs to undergo validation in a representative sample from that population. Model performance during such external validation is assessed in various ways, which can broadly be classified as prediction error (e.g., Brier score), discrimination (e.g., c-statistic), calibration (e.g., calibration intercept and slope), and net benefit $(NB)^1$. Among such metrics, NB is a decision-theoretic one, as it enables direct assessment of the clinical utility of a model (i.e., if a model's expected NB is higher than alternatives, it is expected to confer clinical utility). Due to such strong decision-theoretic underpinnings, and despite its relatively new arrival in the field of predictive analytics, NB has gained significant momentum and has become a standard component of modern external validation studies².

When interpreting the results of a validation study, the finite size of the validation sample means that the assessment of model performance is accompanied by uncertainty. Uncertainty in conventional metrics of model performance is typically communicated using classical inferential methods (e.g., 95% confidence interval [CI] around c-statistic or calibration slope, p-values for comparing the c-statistic of competing models). However, the relevance of such frequentist approach to uncertainty around NB as a decision-theoretic metric is doubtful³⁻⁵.

Decision theory provides an alternative view to the consequences of uncertainty by relating it to the outcome of decisions. Leaving aside, for the sake of simplicity, the issue of risk aversion, the decision-maker should

From Faculty of Medicine and Pharmaceutical Sciences (MS, TYL), and Department of Statistics (PG), The University of British Columbia, Vancouver, British Columbia, Canada; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA (AV); Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands, and Department of Development and Regeneration, KU Leuven, Leuven, Belgium (LW)

^{*}Correspondence to Mohsen Sadatsafavi, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada; email: mohsen.sadatsafavi@ubc.ca

adopt the strategy with the highest expected utility, which, if implementation costs are comparable, is the one with the highest net benefit. While uncertainty around NB should not affect the 'adoption decision', it is associated with utility loss as it hinders our ability to identify the decision with the highest true NB. The extent of uncertainty should thus inform the 'research decision': whether the expected utility loss is large enough to necessitate collecting further evidence. This approach towards uncertainty quantification is referred to as Value of Information (VoI) analysis $6-8$.

VoI methods are widely accepted in health policy-making^{7,9}. However, their relevance to clinical decisionmaking and risk prediction has only recently been highlighted¹⁰. In particular, the expected value of perfect information (EVPI), the expected gain in NB by completely eliminating uncertainty, has been applied to both the development and validation phases of risk prediction models $10,11$. If based on EVPI, the investigator concludes that uncertainty is large and procuring more validation data is warranted, the next natural question is 'how much data should be collected?'. The expected value of sample information (EVSI) is the expected gain in NB by conducting a study of a given sample size (and design)¹². In the context of model validation, EVSI can thus inform the sample size determination of future validation studies.

The aim of the present work is to define EVSI for the external validation phase of a risk prediction model and propose algorithms for its computation. The rest of this manuscript is structured as follows. After outlining the context, we define EVSI for a future study aimed at evaluating the clinical utility of a model in a target population. We propose algorithms for EVSI computation based on bootstrapping when preliminary data from the target populations are available, a beta-binomial modeling approach for binary outcomes when current information can be specified as independent Beta distributions, and a more general algorithm when the current information is expressed as an arbitrary probability distribution. A case study puts the developments in context where we provide practical suggestions on reporting and interpreting EVSI. We conclude by proposing areas of further inquiry.

Methods

Context and notations

We focus on validating a previously-developed risk prediction model in a well-defined new target population. The developments are presented for models for binary responses but are generally applicable to any context where NB can be assessed (e.g., survival outcomes¹³, models for treatment benefit¹⁴). The model is advertised as a function that maps patient characteristics to an estimate of event risk. We acknowledge the relevance of other sources of uncertainty (e.g., missing data, the plausibility that the sample is truly representative of the target population) but focus the developments on sampling uncertainty, and discuss some other uncertainty sources whenever relevant.

VoI analysis is a Bayesian paradigm and requires explicit specification of current information on the performance of the model in the target population. By default, we assume this information is generated from a preliminary validation exercise based on an iid sample **d** of *n* individuals. However, such information can be generated in other ways. For example, one can extrapolate (optimism-corrected) performance of a model from its development sample, or its performance in previous validation studies¹⁵, and accommodate any added uncertainty about the compatibility of the populations (e.g. by quantitatively discounting external information¹⁶). Formal expert elicitation approaches can also be employed to construct distributions around model performance metrics¹⁷. In such instances, **d** can be an abstract entity representing, for example, the expert-elicited information.

Given our current information, we are considering the utility of procuring data of sample of size n^* for a future validation study in the same target population. We are interested in expected utility gain from such a study. We express utility in terms of net benefit (NB), as is quantified and presented in decision curve analysis¹⁸. In a nutshell, NB is based on the specification of a risk threshold, denoted by z , placed on predicted risks such that individuals with predicted risk lower than this threshold are considered low-risk, and those with predicted risk higher than this threshold are classified as high-risk (and therefore are selected for treatment). For individuals with predicted risk precisely equal to *z*, the decision-maker will be ambivalent about the treatment decision. Because among these individuals, treating all means a proportion *z* is properly treated (true positive) while the proportion $1 - z$ is unnecessarily treated (false positive), such ambivalence implies that each false positive has $-z/(1-z)$ times clinical utility of a true positive. Because the true and false positive rates of the model can be estimated at this threshold, this implied exchange rate can be used to evaluate the NB of a model in net true positive or false positive units. Any given model should be compared with at least two 'default' strategies of treating no one and treating all. Treating no one has NB=0 by definition, and NB calculations for treating all follow the same logic as above, but by considering all individuals as positive. In practice, NB is measured over a range of plausible risk thresholds.

Let θ be the set of parameters that fully specify the target population for NB calculations. A common setup for binary outcomes is to define θ as the triplet of prevalence (θ_p) , sensitivity (θ_{se}) , and specificity $(\theta_{sp})^{20}$. We index treating no one, model-based treatment, and treating all by, respectively, subscripts 0,1,2, resulting in the following equation for NBs (for brevity, we drop the notation that indicates quantities are functions of *z*)

$$
NB(i,\theta) = \begin{cases} 0 & i = 0 \quad \text{(treat no one)}\\ \theta_p \theta_{se} - (1 - \theta_p)(1 - \theta_{sp})\frac{z}{1 - z} & i = 1 \quad \text{(use model to decide)}\\ \theta_p - (1 - \theta_p)\frac{z}{1 - z} & i = 2 \quad \text{(treat all)} \end{cases},
$$
(1)

with $\theta = {\theta_p, \theta_{se}, \theta_{sp}}$. For time-to-event outcomes, these quantities are time-dependent and should be defined at a time-horizon of interest¹³. If there are alternative strategies they can also be considered (the above indexing of $NB()$ can accommodate other strategies), but this is omitted from this work for the ease of exposition.

Our current information about θ based on the available evidence is expressed as $P(\theta|\mathbf{d})$. According to Bayes' theorem, $P(\theta|\mathbf{d}) \propto P(\theta)P(\mathbf{d}|\theta)$, indicating that this information is influenced by any prior information we might have had, as well as by what we have learned from **d**.

The expected value of current information

With $P(\theta|\mathbf{d})$ quantifying their knowledge about θ , a risk-neutral decision-maker should pick the strategy with the highest expected NB given the current information:

$$
\mathbb{E}NB_{\text{current information}} = \max_{i} \mathbb{E}_{\theta|\mathbf{d}}NB(i,\theta),\tag{2}
$$

where the expectation is with respect to $P(\theta|\mathbf{d})$. Generally, evaluating this expectation might require a Monte Carlo approach (e.g., via Markov Chain Monte Carlo sampling from *P*(*θ*|**d**)). However, in many instances, this expectation can be more readily obtained. For example, a Bayesian interpretation of the bootstrap allows one to interpret an estimate of *θ* obtained from a bootstrapped copy of **d** as a random draw from the posterior distribution of θ given \mathbf{d}^{21} . However, as the number of bootstrap iterations increases, due to the law of large numbers the average values from such bootstrap samples for each component of *θ* as well as *NB*s converge to their point estimate in the sample. This justifies interpreting the point estimates of *NB* from the sample, as is conducted in conventional decision curve analysis 21 , in a Bayesian framework as the posterior mean under a non-informative prior.

The expected value of perfect information (EVPI)

Details of the reasoning and algorithms behind calculating EVPI is presented previously¹¹. In brief, if we could know the true values of θ , we would have picked the strategy with the highest true NB. We indeed do not have access to the ground truth, but have partial information in terms of $P(\theta|\mathbf{d})$. As such, we can model the consequence of knowing the truth and take its expectation with respect to this distribution:

$$
\mathbb{E}NB_{\text{perfect information}} = \mathbb{E}_{\theta|\mathbf{d}}\max_{i} NB(i,\theta). \tag{3}
$$

The EVPI is then the difference in expected NB of having perfect information versus current information:

$$
EVPI = ENB_{\text{perfect information}} - ENB_{\text{current information}}.\tag{4}
$$

The EVPI is a scalar quantity in NB units and quantifies the expected loss in NB due to uncertainty, or alternatively, the expected gain in NB by completely resolving uncertainty (i.e., conducting a validation study of infinite size). We have proposed a generic algorithm based on bootstrapping to estimate this expectation, as well as an asymptotic approach based on central limit theorem and two-dimensional unit normal loss $integral¹¹$.

The expected value of sample information (EVSI)

The reasoning behind EVSI calculation is similar to that of EVPI, with the modification that instead of knowing the truth, we will have more (but not complete) information about θ , with additional information coming from a future iid sample \mathcal{D}^* of size n^* . With this added information we will have the opportunity to revise our current decision. We will update our knowledge from $P(\theta|\mathbf{d})$ to $P(\theta|\mathbf{d}, \mathcal{D}^*)$, and will select the strategy that has the highest expected *NB*.

The NB of this approach once future data \mathcal{D}^* are obtained is $\max_i \mathbb{E}_{\theta|\mathcal{D}^*,\mathbf{d}} NB(i,\theta)$. We do not know what data we will observe in the future, but we can treat \mathcal{D}^* as a random variable, and take the expectation of this line of reasoning with regard to its predictive distribution:

$$
\mathbb{E}NB_{\text{sample information}} = \mathbb{E}_{\mathcal{D}^*|\mathbf{d}} \max_{i} \mathbb{E}_{\theta|\mathcal{D}^*,\mathbf{d}} NB(i,\theta). \tag{5}
$$

The EVSI is the difference between this ENB and ENB under current information:

$$
EVSI = ENBsample information - ENBcurrent information.
$$
\n(6)

The EVSI is a non-negative scalar quantity in the same NB units as EVPI. It quantifies the expected gain in NB by procuring a further validation sample of a given size. The higher the EVSI, the higher the expected gain from the planned validation study. EVPI, quantifying the expected NB gain by completely resolving uncertainty, puts an upper limit on EVSI.

EVSI computation algorithms

The challenge for EVSI calculation is the two nested expectations. The inner expectation represents updated estimates of NBs after obtaining future data, and the outer expectation is with respect to the predictive distribution of future data. Below we detail three computaion algorithms.

A bootstrap-based algorithm

If the current evidence **d** is in terms of a random sample of size n from the target population of interest, sampling from $P(\theta|\mathbf{d})$ can be performed via the Bayesian bootstrap²¹. The resulting algorithm for EVSI computation is similar to the previously proposed method for EVSI calculations for data-driven economic evaluations²² and can be seen as an extension of the bootstrap method for EVPI computation for external validation studies¹¹.

The Bayesian bootstrap of **d** assigns an improper non-informative prior distribution Dirichlet(0*,* 0*, ...,* 0) across the *n* data points. A random draw from the posterior distribution of the generating population can be materialized by drawing a random weight vector from the Dirichlet $(1, 1, ..., 1)$ distribution. Estimating θ in this weighted sample is akin to drawing a value for θ from its posterior distribution²¹. Further, once the generating population is at hand, the data of the future study (\mathcal{D}^*) can be drawn by sampling from this population. This results in a two-level resampling approach for EVSI calculation explained in Table [1.](#page-4-0)

1. For $j = 1$ to N (number of Monte Carlo simulations)

- (a) Draw **F**, a Bayesian bootstrap*^a* of the data **d**. This is a random draw from the posterior distribution of the population that has generated the sample.
- (b) Compute and record NBs from **F**.
- (c) Record the maximum NB from those calculated in the previous step.
- (d) Draw D[∗] , a random realization of the dataset of the future study, through sampling *n* [∗] observations with replacement from **F**.
- (e) Merge the future and existing data and estimate the expected NBs of each strategy in the pooled sample (this will be $\mathbb{E}_{\theta|\mathcal{D}^*,\mathcal{I}} NB(i,\theta)$). Record maximum NB.

Next *j*

- 2. Take the average of NBs from step [1b](#page-4-1) and pick the maximum value. This is $\mathbb{E}NB_{\text{current information}}^b$.
- 3. Average maximum NB from step [1c.](#page-4-2) This is E*NB*perfect information. From this subtract NB from step [2.](#page-4-3) This is EVPI.
- 4. Average maximum NB from step [1e.](#page-4-4) This is E*NB*sample information. From this subtract NB from step [2.](#page-4-3) This is EVSI.

^{*b*} ENB_{current information} can also be directly evaluated in the original sample without bootstrapping. However, we recommend averaging over bootstrapped values as this approach is consistent with the way other terms are evaluated and this prevents getting occasional negative VoI metrics

Table 1: Bootstrap-based computation of EVSI

The power of this approach is in the flexibility of the bootstrap method in accommodating different types of outcomes and practical considerations in validation studies. For example, if the dataset **d** has non-trivial level of missing data, which affects the amount of information it contains, the step [1b](#page-4-1) in the above algorithm can include an imputation component, generating the population **F** without any missing values (and similarly, step [1d](#page-4-5) can introduce missingness in the data to simulate a real-world validation dataset).

The ordinary bootstrap, which assigns weights from a scaled Multinomial $(1/n, 1/n, ...)$ distribution to observations, is conceptually similar to the Bayesian bootstrap and has been interpreted in a Bayesian way (e.g., in the approximate Bayesian bootstrap employed in missing value imputation²³). In data-driven VoI analyses it generates similar results to the Bayesian bootstrap^{11,22}. It thus can be used in lieu of the Bayesian bootstrap in step [1a.](#page-4-6)

An algorithm based on beta-binomial conjugacy for binary outcomes

In their proposal for a parametric Bayesian NB estimation for binary outcomes, Cruz and Korthauer take advantage of the beta-binomial conjugacy and the fact that the likelihood function for *NB* can be factorized into terms involving prevalence, sensitivity, and specificity. As such, they argue that specifying prior information in terms of independent beta distributions on these quantities will result in corresponding posterior distributions that are also independent beta²⁰. In this case, given that $P(\theta|\mathbf{d})$ is composed of three independent beta distributions, by the same token $P(\theta|\mathbf{d}, \mathcal{D}^*)$ after a realization of \mathcal{D}^* will also be the product of three independent beta distributions. This results in a fast Monte-Carlo approach for EVSI computation as explained in Table [2.](#page-5-0)

Independent beta distributions for each component of *θ* can emerge, from example, if we ask an expert to express their belief about prevalence, sensitivity, and specificity, in terms of fractions. That is, if their best estimate of prevalence is 30%, and their uncertainty is akin to their opinion comping from a sample of 10 individuals, the information can be expressed as $\theta_p \sim \text{Beta}(3, 7)$ (similar for sensitivity and specificity).

Importantly, for binary outcomes and in the absence of missing data, the Bayesian bootstrap approach explained above reduces to this beta-binomial model. This is because the information in a sample **d** can be fully specified via four quantities: the number of true positives (n_{tp}) , false negatives (n_{fn}) , true negatives (n_{tn}) , and false positives (n_{fp}) . The Bayesian bootstrapping of individual observations is akin to assigning an improper prior Dirichlet $(0, 0, 0, 0)$ to these quantities, giving rise to the posterior distribution being of

^a Ordinary bootstrap can also be used - see text

0. Specify the current information for NBs under current information as $\theta_p \sim \text{Beta}(\alpha_p, \beta_p),$ $\theta_{se} \sim \text{Beta}(\alpha_{se}, \beta_{se}),$ $\theta_{sp} \sim \text{Beta}(\alpha_{sp}, \beta_{sp}).$ 1. Plug in the expected values of *θ* from the above distributions in equation [1.](#page-2-0) Record the maximum expected NB. This is $ENB_{current information}$.

-
- 2. For $j = 1$ to N (number of Monte Carlo simulations)
	- (a) Randomly draw from the distribution of θ as specified in step [0.](#page-5-1)
	- (b) Compute true NBs from such draws. Record the maximum NB.
	- (c) Generate \mathcal{D}^* , defined by $\{n_{tp}^*, n_{fn}^*, n_{tn}^*, n_{fp}^*\}$ given the draw from θ obtained in step [2a](#page-5-2) as: n^* ∼ Binomial (n^*, θ_p) (number of positive cases in the future sample), $n_{tp}^* \sim \text{Binomial}(n_+^*, \theta_{se}),$

$$
n_{fn}^* = n_+^* - n_{tp}^*,
$$

$$
n_{tn}^{\mathcal{I}^n} \sim \text{Binomial}(n^* - n_+^*, \theta_{sp}),
$$

$$
n_{fp}^{*} = n^{*} - n_{+}^{*} - n_{tn}^{*}.
$$

(d) Calculate expected NBs given generated \mathcal{D}^* by plugging in the updated estimates of the expected value of θ as follows:

$$
\begin{array}{l} \bar{\theta}^*_p = (\alpha_p + n^*_{tp} + n^*_{fn})/(\alpha_p + \beta_p + n^*), \\ \bar{\theta}^*_{se} = (\alpha_{se} + n^*_{tp})/(\alpha_{se} + \beta_{se} + n^*_{tp} + n^*_{fn}), \\ \bar{\theta}^*_{sp} = (\alpha_{sp} + n^*_{tn})/(\alpha_{sp} + \beta_{sp} + n^*_{tn} + n^*_{fp}). \end{array}
$$

Record the maximum NB. This will be $\mathbb{E}_{\theta | \mathbf{d}, \mathcal{D}^*} NB(i, \theta)$.

Next *j*

- 3. Average NBs from step [2b.](#page-5-3) This is $\mathbb{E}NB_{\text{perfect information}}$. From this subtract ENB from step [1.](#page-5-4) This is EVPI.
- 4. Average NBs from step [2d.](#page-5-5) This is E*NB*sample information. From this subtract ENB from step [1.](#page-5-4) This is EVSI.

Table 2: Computation of EVSI based on beta-binomial conjugacy

the form Dirichlet $(n_{tp}, n_{fn}, n_{tn}, n_{fp})$. Due to the aggregate property of the Dirichlet distribution²⁴, the Dirichlet(0, 0, 0, 0) prior of the Bayesian bootstrap is equal to assigning Beta(0, 0) priors to θ_p , θ_{se} , and θ_{sp} . As such, the beta-binomial algorithms will be equal to the Bayesian bootstrap and can be used instead for VoI computations due to its computational efficiency.

Yet another utility of this approach is that instead of the improper prior employed in the Bayesian bootstrap, the user can specify informative priors. For example, if an independent cross-sectional study in the same target population has estimated outcome prevalence that can be expressed as $Beta(\alpha, \beta)$, then combined with observed data, our current information about prevalence can be expressed as $\theta_p \sim \text{Beta}(\alpha + n_{tp} + n_{fn}, \beta + n_{fp} + n_{tn})$. Further, even in the absence of prior information, proper non-informative or weakly informative priors can be used to rectify some of the previously-identified problems with bootstrap-based VoI calculations at extreme situations. In small validation samples and extreme thresholds, VoI calculations might generate counter-intuitive results¹¹. One instance is when sample estimates of θ_{se} or θ_{sp} are at their extreme (0 or 1). The improper Beta(0*,* 0) prior on sensitivity and specificity can result in improper beta posteriors with one of their two parameters being 0. Therefore, we suggest specifying proper priors (e.g., a flat prior Beta(1*,* 1)) for the three quantities in θ when current information is from an observed sample.

A general algorithm for arbitrary specification of $P(\theta|\mathbf{d})$

In many practical situations our current information $P(\theta|\mathbf{d})$ may not have a simple mathematical form, but one can still draw a Monte Carlo sample of arbitrary size from its distribution (e.g., via Markov Chain Monte Carlo methods). Examples include when $P(\theta_p)$ is constructed from a meta-analysis of prevalence studies, or $P(\theta_{se}, \theta_{sp})$ from a bivariate meta-analysis of the diagnostic accuracy of the test, giving rise to a joint distribution for $P(\theta_{se}, \theta_{sp})$, potentially conditional on prevalence²⁵.

For such a general case where we have a sample from $P(\theta|\mathbf{d})$, the empirical distribution of the sample can be used as the distribution for the current information. The posterior distribution after observing future data can then be approximated by the discrete distribution that puts a mass $w^{(i)} \propto P(\mathcal{D}^*|\theta^{(i)})$ (e.g., a product of Binomial probabilities for binary outcomes) on each observation from this sample. This will result in the generic algorithm explained in Table [3.](#page-7-0)

Results

We used data from GUSTO-I, a clinical trial of multiple thrombolytic strategies for acute myocardial infarction (AMI) , as our case study²⁶. This dataset has been widely used for methodological research in predictive analytics²⁷. All analyses are conducted in R^{28} .

For the present case study, we use a similar set-up as our previous work, with a risk prediction model for 30-day mortality developed using the non-US sample of this dataset, and validated in the US sub-sample. The risk prediction model is a logit model fitted to the entire non-US subset (sample size 17796), with the resulting equation:

 $logit(P(Y=1)) = -2.0842 + 0.0781[age] + 0.4027[AMI location other (vs. inferior)] + 0.5773[AMI location]$ anterior (v. inferior)] + 0.4678 [previous AMI] + 0.7666 [AMI severity (Killip score)] - 0.0775 [min(blood pressure, 100] + 0.0182 [pulse].

Similar to our previous work, we initially assume we have access to only $n = 500$ individuals from the US sub-sample as the source of current information. We randomly selected 500 individuals, without replacement, from the entire 23034 observations in the US sub-sample of GUSTO-I. Later, we will use more observations from the US sub-sample to study how EVSI behaves with the amount of current information. The prevalence of the outcome in the development sample (entire non-US sub-sample) was 0.0723; in the current validation sample it was 0.0860, while in the entire US sub-sample it was 0.0679. We consider the range of relevant thresholds to be 1% -10%.

We start by drawing the decision curve at this range of thresholds, as shown in Figure [1.](#page-8-0) Panel (a) shows the decision curve, and panel (b) shows the difference between the NB of the model and the best alternative

- 0. Quantify current information given arbitrary distribution $P(\theta|\mathbf{d})$. Obtain *M* draws $(\theta^{(1)}, \theta^{(2)}, ..., \theta^{(M)})$ from $P(\theta|\mathbf{d})$.
- 1. Estimate expected NBs under current information by taking expectation of NB terms (in equation [1\)](#page-2-0) with respect to the empirical distribution that puts a mass $w^{(k)}$ of $\propto 1$ on each $\theta^{(k)}$:

$$
NB(i,\theta) = \begin{cases} 0 & i=0\\ \sum_{k=1}^{M} w^{(k)} \{ \theta_p^{(k)} \theta_{se}^{(k)} - (1 - \theta_p^{(k)}) (1 - \theta_{sp}^{(k)}) \frac{z}{1-z} \} / \sum_{k=1}^{M} w^{(k)} & i=1\\ \sum_{k=1}^{M} w^{(k)} \{ \theta_p^{(k)} - (1 - \theta_p^{(k)}) \frac{z}{1-z} \} / \sum_{k=1}^{M} w^{(k)} & i=2 \end{cases}.
$$

Record the maximum expected *NB*. This is E*NB*current information.

- 2. For $j = 1$ to N (number of Monte Carlo simulations)
	- (a) Obtain a random draw from $P(\theta|\mathbf{d})$ (or loop over the draws from step [0\)](#page-7-1). This is taken as the true θ in this iteration.
	- (b) Calculate true NBs given *θ* obtained in the previous step. Record the maximum NB.
	- (c) Generate \mathcal{D}^* of size n^* , defined by $\{n^*_{tp}, n^*_{fn}, n^*_{tp}\}$ given the sample from θ obtained in step [2a:](#page-7-2)
		- n^* ∼ Binomial (n^*, θ_p) (number of positive cases in the future sample),
		- $n_{tp}^* \sim \text{Binomial}(n_+^*, \theta_{se}),$

$$
n_{fn}^* = n_+^* - n_{tp}^*,
$$

$$
n_{tn}^* \sim \text{Binomial}(n^* -
$$

$$
n_{tn}^{*} \sim \text{Binomial}(n^{*} - n_{+}^{*}, \theta_{sp}),
$$

$$
n_{fp}^{*} = n^{*} - n_{+}^{*} - n_{tn}^{*}.
$$

- (d) Update $P(\theta|\mathbf{d})$ by updating the weights $w^{(k)}$ in the empirical distribution of $\theta|\mathbf{d}$ (from step 1) based on the likelihood $P(\mathcal{D}^*|\theta)$. For binary outcomes the weights are:
	- $w^{(k)} \propto P_{Bin}(n_{+}^{*}, n^{*}, \theta_{p}^{(k)}) \times P_{Bin}(n_{tp}^{*}, n_{+}^{*}, \theta_{se}^{(k)}) \times P_{Bin}(n_{tn}^{*}, n^{*} n_{+}^{*}, \theta_{sp}^{(k)}),$

with *PBin*(*x, m, p*) being the probability mass function of the binomial distribution at value *x* for *m* trials and success probability *p*.

(e) Calculate updated NBs given future data by taking expectation of NB terms in step [1](#page-7-3) using the updated weights from step [2d.](#page-7-4)

Next *j*

- 3. Average NBs from from step [2b.](#page-7-5) This is $ENB_{perfect information}$. Subtract from this ENB from step [1.](#page-7-3) This is EVPI.
- 4. Average NBs from step [2e.](#page-7-6) This is E*NB*sample information. Subtract from this ENB from step [1.](#page-7-3) This is EVSI.

Table 3: EVSI computation for binary outcomes for general, non-conjugate distributions

default strategy $(NB_1 - \max(NB_0, NB_2))$ along with its 95% confidence interval (CI, based on the percentile methods using 10,000 bootstraps). The model had higher expected NB than the alternative strategies at the entire range of thresholds of interest.

(a) Decision curve (b) Incremental NB of the model v. best alternative strategy

Figure 1: Decision curve (a) and incremental net benefit of the model v. the best alternative strategy (b). Dashed lines are 95% confidence intervals

Next, we draw the EVPI curve. EVPI and EVSI computations are based on 10ˆ6 Monte Carlo simulations using the aggregate beta-binomial model, with a flat $Beta(1,1)$ prior on each component of θ . The EVPI at 0.01 threshold was 0.00039. At the 0.02 threshold it was 0.00125. The EVPI was 0 at 0.05 and 0.10 thresholds (so EVSI for any n^* will also be 0). We therefore focus on VoI calculations at 0.01 and 0.02 thresholds.

The EVPI curve is presented in Figure [2.](#page-9-0) EVPI quantifies the expected NB loss per decision (every time the model might be used). The overall NB loss due to uncertainty is therefore affected by the expected number of times the medical decision will be made²⁹. In scaling VoI quantities to the population, we apply a similar approach as in our previous work¹¹: a decision-making body in charge of making a national recommendation can consider the model to be applicable to all AMI cases in the US (the target population of the validation sample). There are around $800,000$ AMIs in the US every year³⁰, and a guideline development panel in charge of recommending risk stratification for AMI management can consider all those instances relevant. The scaled VoI values are provided in true positive units on the second Y-axis of the EVPI figure. At the 0.02 threshold, a future validation study can have a maximum benefit equal to gaining 1001 net true positive (individuals who will die within 30 days and are correctly identified as high risk) per year, or avoiding 49069 extra false positive cases per year (individuals who will not die within 30 days.

The EVSI curves are shown in Figure [3.](#page-9-1) Generally, it is expected that EVSI will increase with a larger future study, and will asymptote to EVPI, a pattern that is obvious for both thresholds. The 'diminishing return' pattern is also obvious for both thresholds: the expected NB gain steeply rises at small samples and plateaus as *n* [∗] grows. Similar to EVPI, population scaling is applied to EVSIs and is presented as the second Y-axis of the EVSI curve. At 0.02 threshold, a future study of size $n^* = 500$ has a per-decision EVSI value of 0.00100, corresponding to population value of 804 in true positive cases gained, or 39381 in false positive cases averted.

Figure [4](#page-10-0) provides the results of brief simulation studies that demonstrate how EVSI changes as a function of the amount of current information, represented by the sample size of **d**, the current validation data from which $P(\theta|\mathbf{d})$ is constructed. Starting from a value of 500, we doubled the sample size of the current validation sample, specified the distributions for θ_p , θ_{se} , and θ_{sp} based on this sample, and performed EVSI calculations as above, until reaching *n* = 8*,* 000. Results are provided for both 0.01 and 0.02 thresholds and are the average of 100 independent simulations, in each a new sample (with replacement) from the US subset of GUSTO-I was obtained as the current validation data (100 simulations were considered adequate based on inspecting the standard error of the Monte Carlo simulations).

Figure 2: The expected value of perfect information (EVPI) of the validation sample

Figure 3: EVSI for the case study

As expected, the higher the amount of current information (the larger the *n*), the lower the gain in NB by conducting future studies. When the current validation sample is small, the initial gain in NB by conducting future research can be very large, as evidenced by the steep slope of the EVSI curve. This is not the case when the current information is relatively robust (e.g., based on $n=8,000$, which includes on average 544 events). The comparison between the two thresholds is also informative, as it demonstrates that the amount of gain from future sample is highly dependent on the threshold, even in relative terms. For example, at $z = 0.01$, the EVSI curve when current information is based on $n=1,000$ (dotted blue line) is only slightly lower than the EVSI curve when $n=500$ (dotted black line). At $z=0.02$, EVSI when current information is based on $n=1,000$ (solid blue line) is significantly lower than when the current information is based on $n=500$ (solid black line), across the entire range of future sample sizes.

Figure 4: The expected value of sample information (EVSI) as a function of the sample sample size of the future study (D^{*}) for various levels of current information, represented by the sample size of the current study (*n*) from which $P(\theta)$ is constructed

Discussion

Evaluating the performance of a model in a finite sample is fraught with uncertainty. In this work, we applied the VoI framework to investigate the decision-theoretic consequences of such uncertainty. We defined validation EVSI as the expected gain in NB by obtaining an external validation sample of a given size from the target population of interest. In a case study we showed the feasibility of EVSI calculations, and studied how EVSI is affected by the amount of current information and the sample size of the future study. We suggested scaling the EVSI to the population to quantify the overall gain in clinical utility in true (or false) positive units from conducting an external validation study of a given sample size.

How can EVSI analysis inform study design in predictive analytics? Conducting a validation study is an investment in resources that will generate further information on the performance of a clinical prediction model in a target population. The decision whether to undertake a validation study should ultimately hinge on whether the information gained from such a study is worth the required investments. The EVSI, when scaled to the population, determines the expected return on investment in NB unit. Ultimately, such return should be contrasted against the efforts and resources required for such a study. In decision-analytic (health policy) modeling, EVSI is typically in net monetary units, and when scaled to population, can be compared with the budget of a planned data collection activity. The optimal sample size will be one that maximizes the difference between population EVSI and study costs^{29} . The NB for risk prediction models, on the other hand, is in net true or false positive units, and as such cannot directly be compared with the budget of a validation study. One can always embark on full decision analysis to translate all outcomes to net monetary units, but this will likely require sophisticated decision modeling and context-specific assumptions on long-term outcomes, a process that might take significant amount of time and require further data collection (e.g., to obtain utility weights for outcomes). To us, a main reason for the vast popularity of decision curve analysis is that it provides an assumption-free, reproducible method for NB calculation based on the very same data that are used for studying model calibration and discrimination. We think VoI analysis during model development and validation should generally keep the same spirit. A full decision analysis should be relegated to after an impact analysis has measured the resource-use implications of implementing the model. This, however, means the decision rules for determining the optimal sample size of development and validation studies based on the VoI framework would be different than those used in health policy analysis. This paper deliberately stayed away from proposing such rules, and instead focused on defining concepts and proposing computation methods for EVSI. Proposing such decision rules is detached from EVSI calculations and deserves its own airing.

There are multiple areas of further inquiry. The EVSI framework should also be applied to the development phase of prediction models. This can guide the investigator on whether further development, or moving to validation, should be prioritized. We mainly focused on NB loss due to sampling uncertainty. However, there are several sources of uncertainty, such as whether our existing information on the performance of the model is directly applicable to the target population, or if predictors and outcome are measured with the same quality between the study and usual practice. The comparative statistical and computational performance of the EVSI computations algorithms, and the adequacy of a given number of simulations for each algorithm, should be evaluated in dedicated studies. We also do not claim the algorithms we proposed are the only ones that can be used for EVSI computations. Other algorithms, such as those based on central limit theorem^{31,32}, can prove useful. VoI analysis in decision modeling has received significant boost in computational speed in recent years due to the arrival of algorithms based on non-parametric regression modeling33,34. This approach can facilitate VoI analysis in risk prediction as well. The EVSI defined in this work is for a single, homogeneous target population, and does not consider heterogeneous settings. Consider the hierarchical Bayesian tri-variate model by Wynants et al for NB estimation in multi-center validation studies¹⁹ and imagine a new center is interested in validating this model in their local setting. The posterior predictive distribution from the hierarchical model for a new center (potentially combined with any local information on the performance of the model) can act as 'current information', enabling EVSI calculations. This will be valid and informative insofar as the expected NB gain in that center is concerned. However, in a hierarchical Bayesian framework, information learned from one cluster propagates to others, and thus conducting a validation study in a new center results in change in the distribution of NB in other centers. Such NB gain from learning across clusters in hierarchical settings is not reflected in the EVSI computed for this particular setting. VoI metrics and corresponding computation algorithms for multi-center studies should be developed separately. Further, during external validation, often a secondary aim is to update the model if its performance turns out to be sub-optimal³⁵. Such model revision can take different levels of complexity (from intercept correction to re-estimating regression coefficients³⁶) and one might be interested in the expected yield of a given sample size for such model revision. This will get connected to the VoI concepts for model development. As stated earlier, how VoI metrics for prediction models should inform objective functions for determining the optimal sample size should be debated by the community in the hope of generating consensus and best practice standards.

There is an ongoing debate on the appropriateness of conventional, frequentist metrics of uncertainty when reporting NB of a clinical prediction model^{3–5}. The same concerns can logically be extended to frequentist method for sample size and power calculations around NB^{37-39} . VoI methodology provides a rigorous, utilitarian response to such controversies. The toolbox of VoI methods for clinical prediction models is growing, and perhaps it is time to formalize the role of VoI in uncertainty quantification and design of empirical studies in predictive analytics.

References

- 1. Steyerberg EW, Vergouwe Y. [Towards better clinical prediction models: Seven steps for development](https://doi.org/10.1093/eurheartj/ehu207) [and an ABCD for validation.](https://doi.org/10.1093/eurheartj/ehu207) *European Heart Journal* 2014; 35: 1925–1931.
- 2. Fitzgerald M, Saville BR, Lewis RJ. [Decision curve analysis.](https://doi.org/10.1001/jama.2015.37) *JAMA* 2015; 313: 409–410.
- 3. Kerr KF, Marsh TL, Janes H. [The Importance of Uncertainty and Opt-In v. Opt-Out: Best Practices](https://doi.org/10.1177/0272989X19849436) [for Decision Curve Analysis.](https://doi.org/10.1177/0272989X19849436) 2019; 39: 491–492.
- 4. Capogrosso P, Vickers AJ. [A Systematic Review of the Literature Demonstrates Some Errors in the](https://doi.org/10.1177/0272989X19832881) [Use of Decision Curve Analysis but Generally Correct Interpretation of Findings.](https://doi.org/10.1177/0272989X19832881) *Med Decis Making* 2019; 39: 493–498.
- 5. Vickers AJ, Van Claster B, Wynants L, et al. [Decision curve analysis: Confidence intervals and](https://doi.org/10.1186/s41512-023-00148-y) [hypothesis testing for net benefit.](https://doi.org/10.1186/s41512-023-00148-y) *Diagn Progn Res* 2023; 7: 11.
- 6. Felli J, Hazen G. [Sensitivity analysis and the expected value of perfect information.](https://www.ncbi.nlm.nih.gov/pubmed/9456214) 1998; 18: 95–109.
- 7. Jackson CH, Baio G, Heath A, et al. [Value of Information Analysis in Models to Inform Health Policy.](https://doi.org/10.1146/annurev-statistics-040120-010730) *Annu Rev Stat Appl* 2022; 9: 95–118.
- 8. Heath A, Kunst N, Jackson C. *Value of Information for Healthcare Decision-Making*. 1st ed. Boca Raton: Chapman; Hall/CRC. Epub ahead of print December 2023. DOI: [10.1201/9781003156109.](https://doi.org/10.1201/9781003156109)
- 9. Tuffaha HW, Gordon LG, Scuffham PA. [Value of information analysis in healthcare: A review of](https://doi.org/10.3111/13696998.2014.907170) [principles and applications.](https://doi.org/10.3111/13696998.2014.907170) *J Med Econ* 2014; 17: 377–383.
- 10. Sadatsafavi M, Yoon Lee T, Gustafson P. [Uncertainty and the value of information in risk prediction](https://doi.org/10.1177/0272989X221078789) [modeling.](https://doi.org/10.1177/0272989X221078789) *Medical Decision Making: An International Journal of the Society for Medical Decision Making* 2022; 272989X221078789.
- 11. Sadatsafavi M, Lee TY, Wynants L, et al. [Value-of-Information Analysis for External Validation of](https://doi.org/10.1177/0272989X231178317) [Risk Prediction Models.](https://doi.org/10.1177/0272989X231178317) *Medical Decision Making: An International Journal of the Society for Medical Decision Making* 2023; 43: 564–575.
- 12. Ades A, Lu G, Claxton K. [Expected value of sample information calculations in medical decision](https://doi.org/10.1177/0272989X04263162) [modeling.](https://doi.org/10.1177/0272989X04263162) 2004; 24: 207–227.
- 13. Vickers AJ, Cronin AM, Elkin EB, et al. [Extensions to decision curve analysis, a novel method for](https://doi.org/10.1186/1472-6947-8-53) [evaluating diagnostic tests, prediction models and molecular markers.](https://doi.org/10.1186/1472-6947-8-53) *BMC Med Inform Decis Mak* 2008; 8: 53.
- 14. Vickers AJ, Kattan MW, Sargent DJ. Method for evaluating prediction models that apply the results of randomized trials to individual patients. *Trials*; 8. Epub ahead of print December 2007. DOI: [10.1186/1745-6215-8-14.](https://doi.org/10.1186/1745-6215-8-14)
- 15. Glynn D, Nikolaidis G, Jankovic D, et al. [Constructing Relative Effect Priors for Research Prioritization](https://doi.org/10.1177/0272989X231165985) [and Trial Design: A Meta-epidemiological Analysis.](https://doi.org/10.1177/0272989X231165985) *Med Decis Making* 2023; 43: 553–563.
- 16. Ibrahim JG, Chen M-H, Gwon Y, et al. [The power prior: Theory and applications.](https://doi.org/10.1002/sim.6728) *Stat Med* 2015; 34: 3724–3749.
- 17. O'Hagan A. *Uncertain judgements: Eliciting experts' probabilities*. London: Wiley, 2006.
- 18. Vickers AJ, Elkin EB. [Decision curve analysis: A novel method for evaluating prediction models.](https://doi.org/10.1177/0272989X06295361) 2006; 26: 565–574.
- 19. Wynants L, Riley RD, Timmerman D, et al. [Random-effects meta-analysis of the clinical utility of](https://doi.org/10.1002/sim.7653) [tests and prediction models.](https://doi.org/10.1002/sim.7653) *Stat Med* 2018; 37: 2034–2052.
- 20. Cruz GNF, Korthauer K. Bayesian Decision Curve Analysis with bayesDCA, [http://arxiv.org/abs/23](http://arxiv.org/abs/2308.02067) [08.02067](http://arxiv.org/abs/2308.02067) (2023, accessed 4 January 2024).
- 21. Rubin DB. The Bayesian Bootstrap. *Ann Statist*; 9. Epub ahead of print January 1981. DOI: [10.1214/aos/1176345338.](https://doi.org/10.1214/aos/1176345338)
- 22. Sadatsafavi M, Marra C, Bryan S. [Two-level resampling as a novel method for the calculation of the](https://doi.org/10.1002/hec.2869) [expected value of sample information in economic trials.](https://doi.org/10.1002/hec.2869) *Health Econ* 2013; 22: 877–882.
- 23. Schafer J. [Multiple imputation: A primer.](https://doi.org/10.1177/096228029900800102) *Statistical Methods in Medical Research* 1999; 8: 3–15.
- 24. Broderick T, Jordan MI, Pitman J. Beta Processes, Stick-Breaking and Power Laws. *Bayesian Anal*; 7. Epub ahead of print June 2012. DOI: [10.1214/12-BA715.](https://doi.org/10.1214/12-BA715)
- 25. Li J, Fine JP. [Assessing the dependence of sensitivity and specificity on prevalence in meta-analysis.](https://doi.org/10.1093/biostatistics/kxr008) *Biostatistics* 2011; 12: 710–722.
- 26. investigators G. [An international randomized trial comparing four thrombolytic strategies for acute](https://doi.org/10.1056/NEJM199309023291001) [myocardial infarction.](https://doi.org/10.1056/NEJM199309023291001) *The New England Journal of Medicine* 1993; 329: 673–682.
- 27. Ennis M, Hinton G, Naylor D, et al. [A comparison of statistical learning methods on the gusto](https://doi.org/10.1002/(SICI)1097-0258(19981115)17:21%3C2501::AID-SIM938%3E3.0.CO;2-M) [database.](https://doi.org/10.1002/(SICI)1097-0258(19981115)17:21%3C2501::AID-SIM938%3E3.0.CO;2-M) *Statistics in Medicine* 1998; 17: 2501–2508.
- 28. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing,<https://www.R-project.org/> (2019).
- 29. Willan AR, Goeree R, Boutis K. [Value of information methods for planning and analyzing clinical](https://doi.org/10.1016/j.jclinepi.2012.01.017) [studies optimize decision making and research planning.](https://doi.org/10.1016/j.jclinepi.2012.01.017) *J Clin Epidemiol* 2012; 65: 870–876.
- 30. Virani SS, Alonso A, Aparicio HJ, et al. [Heart Disease and Stroke Statistics-2021 Update: A Report](https://doi.org/10.1161/CIR.0000000000000950) [From the American Heart Association.](https://doi.org/10.1161/CIR.0000000000000950) *Circulation* 2021; 143: e254–e743.
- 31. Marsh TL, Janes H, Pepe MS. [Statistical inference for net benefit measures in biomarker validation](https://doi.org/10.1111/biom.13190) [studies.](https://doi.org/10.1111/biom.13190) *Biometrics* 2020; 76: 843–852.
- 32. Yoon Lee T, Gustafson P, Sadatsafavi M, et al. [Closed-Form Solution of the Unit Normal Loss Integral](https://doi.org/10.1177/0272989X231171166) [in 2 Dimensions, with Application in Value-of-Information Analysis.](https://doi.org/10.1177/0272989X231171166) *Med Decis Making* 2023; 43: 621–626.
- 33. Heath A, Manolopoulou I, Baio G. [A Review of Methods for Analysis of the Expected Value of](https://doi.org/10.1177/0272989X17697692) [Information.](https://doi.org/10.1177/0272989X17697692) *Med Decis Making* 2017; 37: 747–758.
- 34. Heath A, Kunst N, Jackson C, et al. [Calculating the Expected Value of Sample Information in Practice:](https://doi.org/10.1177/0272989X20912402) [Considerations from 3 Case Studies.](https://doi.org/10.1177/0272989X20912402) *Med Decis Making* 2020; 40: 314–326.
- 35. Steyerberg EW, Borsboom GJJM, Houwelingen HC van, et al. [Validation and updating of predictive](https://doi.org/10.1002/sim.1844) [logistic regression models: A study on sample size and shrinkage.](https://doi.org/10.1002/sim.1844) *Statistics in Medicine* 2004; 23: 2567–2586.
- 36. Vergouwe Y, Nieboer D, Oostenbrink R, et al. [A closed testing procedure to select an appropriate](https://doi.org/10.1002/sim.7179) [method for updating prediction models.](https://doi.org/10.1002/sim.7179) *Stat Med* 2017; 36: 4529–4539.
- 37. Riley RD, Debray TPA, Collins GS, et al. [Minimum sample size for external validation of a clinical](https://doi.org/10.1002/sim.9025) [prediction model with a binary outcome.](https://doi.org/10.1002/sim.9025) *Stat Med* 2021; 40: 4230–4251.
- 38. Riley RD, Snell KIE, Ensor J, et al. [Minimum sample size for developing a multivariable prediction](https://doi.org/10.1002/sim.7993) [model: Part Ib -b Continuous outcomes.](https://doi.org/10.1002/sim.7993) *Stat Med* 2019; 38: 1262–1275.
- 39. Riley RD, Snell KI, Ensor J, et al. [Minimum sample size for developing a multivariable prediction](https://doi.org/10.1002/sim.7992) [model: PART II - binary and time-to-event outcomes.](https://doi.org/10.1002/sim.7992) *Stat Med* 2019; 38: 1276–1296.